Freeze-thaw cycle raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-01-10 and is reviewed periodically as new material appears.
After reconstitution, solutions are usually divided into single-use aliquots to limit repeated handling. Each aliquot is stored at a temperature appropriate for the peptide, with -20 °C or -80 °C common for longer-term laboratory storage. Freeze-thaw cycles are minimized because they can cause aggregation, precipitation, or loss of activity. Temperature monitoring and documented storage conditions support reproducibility across experiments. When a peptide is removed from storage, it is typically allowed to equilibrate before opening to reduce condensation.
Receiving a peptide begins with recording its identity, lot number, quantity, and arrival condition. Dry material is often kept in sealed containers with desiccant and an inert headspace to limit moisture and oxygen. Containers should be compatible with the peptide and solvent; some peptides adsorb to certain plastics or glass. Labels should include date, concentration, solvent, and storage location. A centralized inventory with temperature logs helps prevent loss and mix-ups.
Reconstitution introduces new variables. The solvent should match the peptide's solubility profile, and water or buffer quality matters because trace metals and microbes can alter results. Adding solvent gently down the vial wall minimizes foaming, which can denature some sequences. Mixing by gentle inversion or swirling is usually preferred over vigorous vortexing. If a peptide does not dissolve readily, adjusting pH or using a small amount of organic co-solvent may help, but such steps can also affect stability and should be documented.
Quality control links handling to measurable identity and purity. Reverse-phase high-performance liquid chromatography can separate peptide variants and reveal impurities. Mass spectrometry confirms molecular mass and can detect truncations or modifications. These methods are often paired with ultraviolet absorbance or amino acid analysis for concentration. Documentation of instrument settings, column type, and reference standards supports reproducibility. For research materials, acceptance criteria depend on the intended application, and no universal purity threshold applies to all peptides.
Handling begins when a peptide container is opened. Hygroscopic solids can absorb atmospheric water rapidly, so bench work should be brief and containers resealed with fresh desiccant. Weighing or transferring should occur in a low-humidity environment where possible. Static electricity may cause fine powders to cling to surfaces, leading to inaccurate mass measurements. Tools such as antistatic devices or grounded workstations reduce that problem. Good laboratory practice also includes labeling date, lot, and storage condition after each opening.
| Property | Value | Notes |
|---|---|---|
| Container material | Glass or inert plastic | Compatibility depends on peptide and solvent |
| Headspace gas | Nitrogen or argon | Used to limit oxygen exposure |
| Common reconstitution solvent | Water or buffered aqueous solution | Organic co-solvents may be needed for hydrophobic peptides |
| Freeze-thaw stability | Varies by peptide | Aliquoting reduces repeated cycles |
| Documentation | Lot, date, concentration, storage location | Supports traceability and reproducibility |
Receipt and inventory practices begin with inspection of packaging, temperature indicators, and lot-specific documentation. A certificate of analysis typically reports purity, identity, and sometimes residual water or counterion content. Containers should be labeled with the peptide name, lot number, date received, and storage location. Before a sealed vial is opened, it is often equilibrated to room temperature to reduce condensation on the contents. Clean tools, gloves, and a designated workspace limit contamination and accidental adsorption losses.
Aliquoting reduces repeated temperature cycling for solutions and reconstituted samples. If a peptide is supplied as a powder, reconstitution usually involves adding a suitable solvent gently along the vial wall. Mixing by inversion or slow swirling is preferred over vortexing, which can create air-liquid interfaces that promote aggregation or foaming. The resulting solution should be inspected for clarity, particles, and color before storage. Labels on aliquots typically include concentration, solvent, date, and lot number, and open questions remain about the best solvent for every sequence.
Handling begins before a peptide arrives at the bench. Containers should be inspected for cracks, loose caps, or visible moisture, and labels should record identity, lot, and receipt date. Lyophilized material is often allowed to equilibrate to room temperature before opening to prevent condensation on the powder. Gloves and a clean workspace reduce contamination and static-related loss. Once opened, the vial may be purged with inert gas and resealed if the peptide is sensitive to oxygen or humidity. These steps are procedural safeguards rather than guarantees of stability.
Reconstitution introduces new risks because the peptide contacts solvent, air, and container surfaces. The chosen solvent should match the peptide's solubility profile, and buffer salts, pH, and ionic strength can affect dissolution and subsequent stability. Gentle mixing is preferred over vigorous vortexing, which can create interfaces and shear. If the solution is not clear, the cause may be incomplete dissolution, aggregation, or insoluble counter-ions rather than a simple concentration problem. Filtration is sometimes used, but filters can adsorb peptides and alter measured concentration.
Cold-chain practice relies on documented temperature ranges, calibrated monitoring, and minimized excursions. Shipments may use insulated boxes, phase-change materials, or dry ice, with data loggers to record conditions. Upon receipt, the recipient should verify the logger trace and place items into long-term storage promptly. Repeated warming and cooling during transfers can be more harmful than a single controlled excursion. For solutions, dividing material into single-use aliquots reduces the number of thawing and refreezing events and limits repeated opening of the same container.
Reconstitution is a critical handling step. The appropriate solvent—often sterile water, phosphate-buffered saline, or a water-acetonitrile mixture—is chosen based on peptide solubility. Adding solvent gently down the vial wall and swirling, rather than vortexing, reduces foaming and shear stress. The resulting solution should be clear; visible particles indicate incomplete dissolution or contamination. Concentration is recorded accurately because it affects subsequent use. If the peptide is not fully soluble, a small amount of organic solvent or a different buffer may be required, but this changes the final composition.
After reconstitution, solutions are divided into single-use aliquots and stored at -80°C. Labels include peptide name, concentration, buffer composition, date, and lot number. Freeze-thaw cycles are minimized by thawing only the needed aliquot on ice or at room temperature. Some peptides benefit from the addition of a carrier protein, such as bovine serum albumin, or a cryoprotectant like glycerol to reduce adsorption to plastic. Glass vials with low-binding surfaces are preferred for dilute solutions. Shipping of frozen aliquots uses dry ice and insulated containers to maintain the cold chain.
=== Speed: Bubnoff unit === The Bubnoff unit is defined as 1 micrometre per year (3.169×10−14 m/s), or one millimeter per 1,000 years. It is employed in geology to measure rates of lowering of earth surfaces due to erosion.
Fatty acids with an odd number of carbons are found in the lipids of plants and some marine organisms. Many ruminant animals form a large amount of 3-carbon propionate during the fermentation of carbohydrates in the rumen. Long-chain fatty acids with an odd number of carbon atoms are found particularly in ruminant fat and milk. Chains with an odd-number of carbons are oxidized in the same manner as even-numbered chains, but the final products are propionyl-CoA and acetyl-CoA. Propionyl-CoA is first carboxylated using a bicarbonate ion into a D-stereoisomer of methylmalonyl-CoA. This reaction involves a biotin co-factor, ATP and the enzyme propionyl-CoA carboxylase. The bicarbonate ion's carbon is added to the middle carbon of propionyl-CoA, forming a D-methylmalonyl-CoA. However, the D-conformation is enzymatically converted into the L-conformation by methylmalonyl-CoA epimerase. It then undergoes intramolecular rearrangement, which is catalyzed by methylmalonyl-CoA mutase (requiring B12 as a coenzyme) to form succinyl-CoA. The succinyl-CoA formed then enters the citric acid cycle. However, whereas acetyl-CoA enters the citric acid cycle by condensing with an existing molecule of oxaloacetate, succinyl-CoA enters the cycle as a principal in its own right. Thus, the succinate just adds to the population of circulating molecules in the cycle and undergoes no net metabolization while in it.
Larson received media attention for scolding members of Congress for shutting down the government on September 30, 2013. Larson was among the 46 Democrats who voted against final passage of the Fiscal Responsibility Act of 2023 in the House.
==== Quantum dot in hybrid solar cells ==== Colloidal quantum dots are also used in inorganic–organic hybrid solar cells. These solar cells are attractive because of the potential for low-cost fabrication and relatively high efficiency. Incorporation of metal oxides, such as ZnO, TiO2, and Nb2O5 nanomaterials into organic photovoltaics have been commercialized using full roll-to-roll processing. A 13.2% power conversion efficiency is claimed in Si nanowire/PEDOT:PSS hybrid solar cells.
Sources: en.wikipedia.org
=== Late stage === During the final stage, known as the late-stage or severe stage, there is complete dependence on caregivers. Language is reduced to simple phrases or even single words, eventually leading to complete loss of speech. Despite the loss of verbal language abilities, people can often understand and return emotional signals. Although aggressiveness can still be present, extreme apathy and exhaustion are much more common symptoms. People with Alzheimer's disease will ultimately not be able to perform even the simplest tasks independently; muscle mass and mobility deteriorate to the point where they are bedridden and unable to feed themselves. The cause of death is usually an external factor, such as infection of pressure ulcers or pneumonia, not the disease itself. In some cases, there is a paradoxical lucidity immediately before death, where there is an unexpected recovery of mental clarity.
=== From primary cancer to the meninges === NM is a secondary cancer meaning that it is the result of neoplastic cells that have metastasized from a primary cancer site. These cancers develop an enzyme that is able to break down blood vessels at a microscopic level. These cells enter the blood vessels and travel across the body. Once the brain is reached, they break down the blood–brain barrier to enter the Cerebrospinal Fluid (CSF). There the cancerous cells seed and disseminate into the leptomeninges which are composed of the arachnoid and the pia. The CSF continues to carry neoplastic cells through the brain tracts and spreads the cancerous cells. Lung cancer, breast cancer, and melanoma comprise the majority of solid tumors spreading to the leptomeninges. Although rare, meningeal carcinomatosis can arise from cervical cancer. Only eight cases of MC arising from squamous cell carcinoma of the uterine cervix are previously reported in the literature. Since NM is a result of primary cancer metastasis and can develop from primary brain tumors or parenchymal metastasis when tumor cells are lodged in small central nervous system (CNS) vasculature, causing local ischemia and vessel damage which result in tumor spillage into the Virchow-Robin spaces and providing access to the subarachnoid space.
Myositis Pulmonary involvement: Diffusion capacity < 70% of normal values Pulmonary hypertension Proliferative vascular lesions on lung biopsy Raynaud's phenomenon or esophageal hypomotility Swollen hands Anti-ENA antibody N 1:10,000 and anti-U1 RNP antibody positive and anti-Sm negative Minor criteria:
Sources: en.wikipedia.org
==== Individual droplet addressability ==== DMF allows for droplet level addressability, meaning individual droplets can be treated as spatially distinct microreactors. This level of droplet control is important for workflows where reactions are sensitive to the order of reagent mixing and incubation times, but where the optimal values of these parameters may still need to be determined. These types of workflows are common in cell-free biology, and Liu et al. were able to demonstrate a proof-of-concept DMF-based strategy for carrying out remote-controlled cell-free protein expression on an OpenDrop chip.
== History == The main goal of the identification of the first aldosterone antagonists, which happened during the 1950s, was to identify inhibitors of aldosterone activity. In those times, the main use of aldosterone was recognized as the control of renal sodium and the excretion of potassium. Hans Selye, a Hungarian-Canadian endocrinologist, studied the effects of aldosterone antagonists on rats and found that the use of one of the first aldosterone antagonists, spironolactone, protected them from aldosterone-induced cardiac necrosis. The same year, 1959, spironolactone was launched as a potassium-sparing diuretic. It became clear years later that aldosterone antagonists inhibit a specific receptor protein. This protein has high affinity for aldosterone but also for cortisol in humans and corticosterone in mice and rats. For this reason, aldosterone antagonists were called mineralocorticoid receptor antagonists. There have been three major waves in the pharmaceutical industry when it comes to research and development of mineralocorticoid receptor antagonists: The first wave took place within Searle Laboratories. This company identified, shortly after the purification of aldosterone, steroid-based spironolactone as the first anti-mineralocorticoid. The second wave was all about discovering much more specific steroidal anti-mineralocorticoids. The main active companies were Searle, Ciba-Geigy, Roussel Uclaf and Schering AG. Around 50 years after Selye's work, several pharmaceutical companies began drug discovery programs.
== Research and career == Olabisi was a postdoctoral researcher at Rice University, where she was awarded a postdoctoral fellowship from the National Space Biomedical Research Institute, and City of Hope National Medical Center. There, she investigated how mother-of-pearl (nacre) gets its natural strength and resilience with the hope to recreate it synthetically, by patterning hydrogels with nacre proteins. Olabisi's first faculty position was at Rutgers University; today she is an assistant professor at UC Irvine. Her research looks to make wounds heal faster using cell therapy, work that could revolutionize the recovery time of people who require plastic surgery. By combining hydrogels with proteins, cellular repair can occur faster. She is an inventor on a patent describing growing bone using microencapsulated cells releasing bone morphogenetic proteins. She found that she could entrap certain cells into hydrogels to deliver the hormone insulin, which helps to heal diabetic wounds. In 2018 she became a National Science Foundation CAREER Award grant holder, exploring chronic wounds. She is working on combining mesenchymal stem cells and insulin producing cells for dual cell therapies. She has studied the way that the body adapts to the space environment, in order to identify mechanisms that protect astronauts from the effects of microgravity, by using tissue engineering approaches to stimulate growth, regeneration, and repair.
Sources: en.wikipedia.org
Dry peptides are generally kept in sealed, desiccated containers at low temperature, often -20 °C or colder. Protection from light, moisture, and oxygen helps slow degradation. The exact condition depends on the peptide sequence and supplier guidance.
Aliquoting divides a solution into smaller portions so that each portion is handled once. This reduces repeated freeze-thaw cycles and limits contamination risk. It also makes it easier to track usage and maintain consistent test conditions.
Refreezing is possible for some peptides but can promote aggregation or precipitation. The effect depends on the peptide, solvent, concentration, and freezing rate. Many laboratory protocols therefore recommend single-use aliquots instead of repeated refreezing.
Aliquoting divides a stock into portions that can be thawed once and used without returning the whole batch to storage. This limits temperature cycling and reduces the chance of contamination or concentration changes. It also makes it easier to track how many portions remain.